Skip to content

Outcomes and Policy Research

Chisholm-Burns

Biography
Marie A. Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP, FAST, is Dean and Professor of the University of Tennessee Health Science Center College of Pharmacy and Professor of Surgery in the College of Medicine. She received her BS in Psychology and General Studies (Emphasis in Biology) from Georgia College, BS in Pharmacy and Doctor of Pharmacy degrees from The University of Georgia, Master of Public Health from Emory University, and Master of Business Administration from the University of Memphis. She completed her residency at Mercer University Southern School of Pharmacy and at Piedmont Hospital in Atlanta, Georgia. Dr. Chisholm-Burns is Founder and Director of the Medication Access Program which increases medication access to transplant recipients. She has also served in numerous elected leadership positions in several different professional organizations, has worked in multiple pharmacy settings, and is a member of the National Academies of Practice. She serves as a member of government organizations, such as the Food and Drug Administration. With more than 310 publications and approximately $10 million in external funding as principal investigator from organizations such as the National Institutes of Health and several foundations, Dr. Chisholm-Burns is a prolific scholar. She has a broad background in pharmacy, with specific training and expertise in the following areas: (1) health care, medication, and medication therapy management access; (2) health disparities; (3) pharmacist-provided interventions to improve patient health and economic outcomes; (4) contributions of pharmacists to direct patient care; (5) medication adherence; (6) solid-organ transplant; and (7) scholarship of teaching and learning/education research.  In 2008 and 2011, textbooks co-edited by Dr. Chisholm-Burns, Pharmacotherapy Principles and Practice and Pharmacy Management, Leadership, Marketing, and Finance, respectively, received the Medical Book Award from the American Medical Writers Association. Additionally, she has received numerous awards and honors including the Robert K. Chalmers Distinguished Pharmacy Educator Award from the American Association of Colleges of Pharmacy (AACP), the Clinical Pharmacy Education Award from the American College of Clinical Pharmacy, the Daniel B. Smith Practice Excellence Award from the American Pharmacists Association (APhA), the Rufus A. Lyman Award for most outstanding publication in the American Journal of Pharmaceutical Education (1996 and 2007), the Nicholas Andrew Cummings Award from the National Academies of Practice, the Award of Excellence from the American Society of Health-System Pharmacists (ASHP), the Pharmacy Practice Research Award (2011 and 2014) and Award for Sustained Contributions to the Literature from the ASHP Foundation, the Research Achievement Award from APhA, the Clinician of Distinction Award from the American Society of Transplantation, the Paul R. Dawson Biotechnology Award from AACP, the Chauncey I. Cooper Pharmacist Leadership Award from the National Pharmaceutical Association, and the ASHP/Association of Black Health-Systems Pharmacists Joint Leadership Award. Dr. Chisholm-Burns is also a Fulbright Scholar.
Selected Publications

Peer-reviewed Journal Articles since 2012 (39 out of 140):

  1. Chisholm-Burns M, Erickson S, Spivey C, Kaplan B. Health-related quality of life and employment among renal transplant recipients. Clinical Transplantation 2012;26:411-417.
  1. Chisholm-Burns MA, Spivey CA, Billheimer D, Schlesselman LS, Flowers SK, Hammer D, Engle JP, Nappi J, Pasko MT, Ross LA, Sorofman B, Rodrigues HA, Vaillancourt AM. Multi-institutional study of women and underrepresented minority faculty in academic pharmacy: 20 years of successes, challenges, and opportunities. American Journal of Pharmaceutical Education 2012;76(1):Article 7.
  1. Chisholm-Burns M, Pinsky B, Parker G, Johnson P, Arcona A, Buzinec P, Chakravati P, Good M, Cooper M. Factors influencing immunosuppressant medication adherence in renal transplant recipients. Clinical Transplantation 2012;26:706-713.
  1. Chisholm-Burns MA, Spivey CA, Swift Martin J, Wyles C, Ehrman C, Schlesselman L. Five-year analysis of peer review publications of pharmacy practice faculty. American Journal of Pharmaceutical Education 2012;76(7): Article 127.
  1. Chisholm-Burns M, Spivey C. The “cost” of medication nonadherence: consequences we can no longer afford to accept. Journal of the American Pharmacists Association 2012; 52:823-826.
  1. Chisholm-Burns M, Spivey C, Sredzinski E, Butler S. Intervention toolbox to promote immunosuppressant therapy adherence in adult renal transplant recipients. Journal of the American Pharmacists Association 2012; 52:816-822.
  1. Gorevski E, Succop P, Sachdeva J, Cavanaugh T, Volek P, Heaton P, Chisholm-Burns M, Martin-Boone J. Is there an association between immunosuppressant therapy medication adherence and depression, quality of life, and personality traits in the kidney and liver transplant population? Patient Preference and Adherence 2013;7:301-307.
  1. Gourley DR, Vaidya VA, Hufstader MA, Ray MD, Chisholm-Burns MA. An international capstone experience for pharmacy students. American Journal of Pharmaceutical Education 2013;77:Article 50.
  1. Lee JK, Slack MK, Martin J, Ehrman C, Chisholm-Burns M. Geriatric patient care by U.S. pharmacists in healthcare teams: systematic review and meta analyses. Journal of the American Geriatric Society 2013;61(7):1119-1127.
  1. Chisholm-Burns MA, Spivey CA, Graff Zivin J, Lee JK, Sredzinski E, Tolley EA. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. American Journal of Transplantation 2013;13:2364-2373.
  1. DiPiro JT, Chisholm-Burns MA. Fail fast. American Journal of Pharmaceutical Education 2013;77(8):Article 159.
  1. 12. Weng FL, Chandwani S, Kurtyka KM, Zacker C, Chisholm-Burns MA, Demisse K. Prevalence and correlates of medication non-adherence among kidney transplant recipients more than 6 months post-transplant. BMC Nephrology 2013;14:261.
  1. Spivey CA, Chisholm-Burns MA, Damadzadeh B, Billheimer D. Determining the effect of immunosuppressant adherence levels on graft failure risk among renal transplant recipients. ClinicalTransplantation 2014;28:96-104.
  1. Spivey CA, Chisholm-Burns MA, Garrett C, Duke KM. Serving underserved transplant recipients: experience of a medication access program. Patient Preference and Adherence 2014;8:613-619. 
  1. Wang J, Qiao Y, Shih YC, Spivey CA, Dagogo-Jack S, Wan JY, White-Means SI, Cushman WC, Chisholm-Burns MA. Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. Journal of PharmaceuticalHealth Services Research 2014;5(2):109-118.
  1. Tsapepas D, Langone A, Chan L, Wiland A, McCague K, Chisholm-Burns M*. A longitudinal assessment of adherence with immunosuppressive therapy following kidney transplantation from the Mycophenolic Acid Observational Renal Transplant (MORE) Study. Annals of Transplantation 2014;19:174-181. *senior author
  1. Brown RO, Spivey CA, Chisholm-Burns MA, Byrd DC. Three-year assessment of Advanced Pharmacy Practice Experience change requests at a large public college of pharmacy. Currents in Pharmacy Teaching and Learning 2014; 6:767-72.
  1. Chisholm-Burns M, Spivey CA, Phelps S, McDonough S, Byrd D. Evaluation of student factors associated with pre-NAPLEX scores. American Journal of Pharmaceutical Education 2014;78(10): Article 180.
  1. Wang J, Qiao Y, Shih YC, Jamison, JJ, Spivey CA, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA. Effects of Medicare Part D on disparity implications of medication therapy management eligibility criteria. American Health and Drug Benefits 2014;7:346-358.
  1. Wang J, Zhang Z, Spivey C, Chisholm-Burns M. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population. Research in Social and Administrative Pharmacy 2015;10:904-917.
  1. Farland MZ, Franks AS, Barlow PB, Rowe AS, Chisholm-Burns M. Assessment of student study patterns, performance, and long-term knowledge retention following use of didactive lecture compared to team-based learning. Currents in Pharmacy Teaching and Learning 2015;7(3):317-323. 
  1. Wang J, Shih Y-C, Qin Y, Young T, Thomas Z, Spivey CA, Solomon D, Chisholm-Burns M. Trends in Medicare Part D medication therapy management eligibility criteria. AmericanHealth & Drug Benefits 2015;8(5):247-255. 
  1. Chisholm-Burns M, Spivey CA. Factors associated with student pharmacist philanthropy to the college before and after graduation. American Journal of Pharmaceutical Education 2015;79(7): Article 102.
  1. Wang J, Qiao Y, Shih YC, Jarrett-Jamison J, Spivey CA, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA. Potential health implications of medication therapy management eligibility criteria in the Patient Protection and Affordable Care Act across racial and ethnic groups. Journal of Managed Care & Specialty Pharmacy 2015;31:993-1003.
  1. Chisholm-Burns M, Gatwood J, Spivey CA. Economic analysis of obtaining a PharmD degree and a career as a pharmacist. American Journal of Pharmaceutical Education 2015;79(8):Article 117.
  1. McDonough SLK, Alford EL, Finks SW, Parker RB, Chisholm-Burns MA, Phelps SJ. Student pharmacists’ perceptions of a composite examination in their first professional year. American Journal of Pharmaceutical Education 2016;80(1): Article 4. 
  1. Chisholm-Burns MA, Spivey CA, Tolley EA, Kaplan EK. Medication therapy management and adherence among US renal transplant recipients. Patient Preference and Adherence 2016;10:703-709.
  1. Chisholm-Burns MA, Gatwood J, Spivey CA, Dickey S. Break-even income analysis of pharmacy graduates compared to high school and college graduates. American Journal of Pharmaceutical Education 2016;80(3): Article 44. 
  1. Chisholm-Burns MA, Gatwood J, Spivey CA, Dickey S. Net income of pharmacy faculty compared to community and hospital pharmacists. American Journal of Pharmaceutical Education 2016;80(7): Article 117. 
  1. Madran BB, Karayurt Ö, Spivey CA, Chisholm-Burns MA*. Validity and reliability of the Immunosuppressant Therapy Adherence Scale in Turkish transplant recipients. Turkiye Klinikleri Journal of Nursing 2016;8(4):325-334. *senior author
  1. Woods TM, Acosta WR, Chung EP, Cox AG, Garcia GA, Klucken JR, Chisholm-Burns MA*. Academic freedom should be redefined: point and counterpoint. American Journal of Pharmaceutical Education 2016;80(9): Article 146. *senior author
  1. Wang J, Qiao Y, Spivey C, Li C, Clark C, Den Y, Liu F, Tillman J, Chisholm-Burns M. Disparity implications of proposed 2015 Medicare eligibility criteria for medication therapy management services. Journal of Pharmaceutical Health Services Research 2016; 7(4):209-215. 
  1. Chisholm-Burns MA, Spivey CA, Hagemann T, Josephson MA. Women in leadership and the bewildering glass ceiling. American Journal of Health-System Pharmacy 2017;74:312-324. 
  1. Hohmeier K, Spivey C, Chisholm-Burns M. A community-based partnership collaborative practice agreement project to teach innovation in care delivery. Currents in Pharmacy Teaching and Learning 2017;9:473-478. 
  1. Chisholm-Burns MA, Spivey CA, Gatwood J, Wiss A, Hohmeier K, Erickson SR. Evaluation of racial and socioeconomic disparities in medication pricing and pharmacy access and services. American Journal of Health-System Pharmacy 2017;74(10):653-668. 
  1. Chisholm-Burns MA, Spivey CA, Jaeger M, Williams J, George C. Development of an instrument to measure pharmacy student attitudes toward social media professionalism. American Journal of Pharmaceutical Education 2017;81(4): Article 65. 
  1. Chisholm-Burns MA, Spivey CA, Byrd DC, McDonough SLK, Phelps SJ. Examining the association between the NAPLEX, Pre-NAPLEX, and pre and post admission factors. American Journal of Pharmaceutical Education 2017;81(5): Article 86.
  1. Hohmeier KC, Spivey CA, Boldin S, Moore TB, Chisholm-Burns M. Implementation of a health information exchance into community pharmacy workflow. Journal of the American Pharmacists Association 2017;57:608-615. 
  1. Chisholm-Burns MA, Spivey CA, Jaeger MC, Williams, JS. Associations between pharmacy students’ attitudes toward debt, stress, and student loans. American Journal of Pharmaceutical Education 2017;81(7): Article 5918.

 

Books (4 out of 17):

  1. Chisholm-Burns MA, Vaillancourt A, Shepherd M (eds.). Pharmacy Management, Leadership, Marketing, and Finance. 2nd ed. Burlington, MA: Jones and Bartlett Learning; 2014.
  1. Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT (eds). Pharmacotherapy Principles and Practice. 4th Edition. New York: McGraw-Hill; 2016. 
  1. Katz MD, Matthias KR, Chisholm-Burns MA (eds.). Pharmacotherapy Principles and Practice Study Guide. A Care Plan Approach. 4th Edition. New York: McGraw-Hill; 2016. 

4. Chisholm-Burns MA.  How to Prepare for the PCAT. 7th Edition. Hauppauge, NY: Barron’s Educational Series, Inc.; 2017. (360 pages).

 

Gatwood

Description

Dr. Gatwood’s overarching focus is on improving medication adherence and health outcomes associated with chronic disease. His work approaches this from two distinct yet related methods: 1) identifying populations with poor medication use and determining the factors related to nonadherence using database analyses; and 2) developing and testing technology-focused behavioral interventions aimed at improving medication use and other health-related behaviors. While at UTHSC, this has included analyzing veterans’ antidiabetic medication use patterns for racial and regional variation in adherence and outcomes, testing the effectiveness of tailored text messages to improve diabetes self-care activities among underserved African American adults with diabetes, using real-time mobile monitoring to improve glaucoma medication adherence, determining the impact of clinical pharmacy services on medication use and short-term health outcomes, and, most recently, examining oral anticancer medication adherence and its initiation on adherence to other chronic disease medications.

Dr. Gatwood can be reached at jgatwood@utshc.edu or 615-532-3403.
Members and Collaborators

Dr. Csaba Kovesdy, UTHSC College of Medicine (Nephrology) and Memphis VA Medical Center

Dr. Jim Bailey, UTHSC College of Medicine (Internal Medicine)
Projects
  • Improving Self-Care Decisions of Medically Underserved African-Americans with Uncontrolled Diabetes: Effectiveness of Patient-Driven Text Messaging versus Health Coaching (PI: Jim Bailey; PCORI Project Program Award SC15-1503-28336)
  • The influence of race on medication adherence and health outcomes in veterans with diabetes (UTHSC iRISE KL2) 
  • Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma (ClinicalTrials.gov: NCT03194828)
Selected Publications
  1. Gatwood J, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, Kovesdy CP. Disparities in Initial Oral Antidiabetic Medication Adherence among Veterans with Incident Diabetes.  J Manag Care Spec Pharm (in press)
  2. Gatwood J, Johnson J, Jerkins B. Adherence to topical glaucoma medication: Comparing a new wireless device and self-reported measures. J Glaucoma (in press)
  3. Gatwood J, Hohmeier KC, Farr G, Eckel SF. A Comparison of Approaches to Student Pharmacist Business Planning in Pharmacy Practice Management. Am J Pharm Educ (epub ahead of print). Article ajpe6279
  4. Gatwood J, Gatwood K, Gabre E, Alexander M. Impact of clinical pharmacists in outpatient oncology practices: A review. Am J Health Syst Pharm 2017; 74(19): 1549-1557. 
  5. Gatwood J, Balkrishnan R, Erickson SR, An LC, Piette JD, Farris KB. The impact of tailored text messages on health beliefs and medication adherence in adults with diabetes: A randomized pilot study. Res Soc Adm Pharm 2016; 12(1): 130-140. PubMed PMID: 25980582.

 

Renfro

Description and Biography

Chelsea Renfro, PharmD is an AssistantS Professor in the Department of Clinical Pharmacy and Translational Science at the University of Tennessee Health Science Center.  She received her PharmD at East Tennessee State University Bill Gatton College of Pharmacy.  After receiving her PharmD, Dr. Renfro completed a PGY1 pharmacy practice residency at Community Care of North Carolina and the UNC Eshelman School of Pharmacy with a focus in ambulatory care and transitions of care.  She then completed a postdoctoral fellowship in community pharmacy research at the UNC Eshelman School of Pharmacy.  Dr. Renfro’s research interests focus on 1) interprofessional communication and 2) implementation of clinical pharmacy services in the community pharmacy setting.  Through her research, she hopes to change the way community pharmacy is portrayed and delivered to the population of the United States while influencing reimbursement strategies that affect health policy.  

Dr. Renfro can be reached at crenfro@uthsc.edu or 901-448-3541.
Members and Collaborators
  • Stefanie Ferreri, PharmD at UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina
  • Sue Blalock, PhD at UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina
  • Jan Busby-Whitehead, MD at UNC School of Medicine, Chapel Hill, North Carolina
  • Kea Turner, MPH, MA at UNC Gillings School of Global Public Health, Chapel Hill, North Carolina
  • Chris Shea, PhD at UNC Gillings School of Global Public Health, Chapel Hill, North Carolina
  • Joel Farley, PhD at University of Minnesota College of Pharmacy, Minneapolis, Minnesota
Projects
  1. Ferreri S, Renfro CP, Blalock S, Farley J, Busby-Whitehead J. Implementing an Integrative Falls Prevention Program for High-Risk Patients in Community Pharmacies. Center for Disease Control. Sep 2016-Aug 2019. Awarded $1,049,999. Subcontract $21,353.
  2. Hohmeier K, Wheeler J, Renfro CP, Wang J. Exploring Community Pharmacy Leadership Perceptions of Pharmacy Technicians. Pharmacy Technician Certification Board.
  3. Renfro CP, Turner K, Shea C, and Ferreri S. Removing barriers to organizational change in community pharmacies: An analysis of the success and challenges of implementing enhanced services. Community Pharmacy Foundation. November 2017-May 2018. Awarded $28,000.
  4. Renfro CP and Ferreri S. Integrating Community Pharmacists Into Team-Based Care. Community Pharmacy Foundation. March 2017-December 2017. Awarded $25,000.
  5. Renfro CP, Patti M, Ballou J, Ferreri S. An Integrated Stage-Based Framework for Implementation of a Medication Synchronization Program in Community Pharmacies.

 

Spivey

Biography

Christina A. Spivey, PhD, LMSW, is an Assistant Professor in the Department of Clinical Pharmacy and Translational Science of the University of Tennessee Health Science Center College of Pharmacy and a member of the UTHSC Institute of Health Outcomes and Policy. She received a PhD in Social Work from The University of Georgia, a Master of Social Service Administration degree from the University of Chicago, and a Bachelor’s degree in Justice from American University. Dr. Spivey has more than 60 publications (peer-reviewed journal articles and book chapters) spanning such fields as social work, geriatrics, public health, and pharmacy. Her research efforts are largely focused on (1) medication adherence and related outcomes in chronic disease state patient populations such as transplant and atrial fibrillation; (2) disparities and outcomes associated with medication therapy management; (3) medication access; and (4) academic pharmacy and scholarship of teaching and learning. She has served as Co-Principal Investigator and Co-Investigator on competitive extramural grants from multiple funding agencies including the NIH, foundations, and industry. She served as co-author on two projects which received the Pharmacy Practice Research Award (2011 and 2014) from the American Society of Health-System Pharmacists (ASHP) Foundation.

Selected Publications

Peer-reviewed Journal Articles since 2012 (33 of 58 total):

  1. Chisholm-Burns, M., Erickson, S., Spivey, C., & Kaplan, B. (2012). Health-related quality of life and employment among renal transplant recipients. Clinical Transplantation,26, 411-417.
  1. Chisholm-Burns, M.A., Spivey, C.A., Billheimer, D., Schlesselman, L.S., Flowers, S.K., Hammer, D., Engle, J.P., Nappi, J., Pasko, M.T., Ross, L.A., Sorofman, B., Rodrigues, H.A., & Vaillancourt, A.M. (2012). Multi-institutional study of women and underrepresented minority faculty in academic pharmacy: 20 years of successes, challenges, and opportunities. American Journal of Pharmaceutical Education,76(1), Article 7. 
  1. Chisholm-Burns, M.A., Spivey, C.A., Martin, J., Wyles, C., Ehrman, C., & Schlesselman, L. (2012). Five-year analysis of peer review publications of pharmacy practice faculty. American Journal of Pharmaceutical Education, 76(7), Article 127.
  1. Chisholm-Burns, M., & Spivey, C. (2012). The “cost” of medication nonadherence: consequences we can no longer afford to accept. Journal of the American Pharmacists Association, 52, 823-826
  1. Chisholm-Burns, M., Spivey, C., Sredzinski, E., & Butler, S. (2012). Intervention toolbox to promote immunosuppressant therapy adherence in adult renal transplant recipients. Journal of the American Pharmacists Association, 52, 816-822.
  1. Chisholm-Burns, M.A., Spivey, C.A., Graff Zivin, J., Lee, J.K., Sredzinski, E. & Tolley, E.A. (2013). Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. American Journal of Transplantation,13, 2364-2373.
  1. Spivey, C.A., Chisholm-Burns, M.A., Damadzadeh, B, & Billheimer, D. (2014). Determining the effect of immunosuppressant adherence levels on graft failure risk among renal transplant recipients. Clinical Transplantation,28, 96-104.
  1. Spivey, C.A., Chisholm-Burns, M.A., Garrett, C., & Duke, K.M. (2014). Serving underserved transplant recipients: experience of a medication access program. Patient Preference and Adherence, 8, 613-619.
  1. Wang, J., Qiao, Y., Shih, Y.C., Spivey, C.A., Dagogo-Jack, S., Wan, J.Y., White-Means, S.I., Cushman, W.C., & Chisholm-Burns, M.A. (2014). Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. Journal of PharmaceuticalHealth Services Research,5(2), 109-118.
  1. Brown, R.O., Spivey, C.A., Chisholm-Burns, M.A., & Byrd, D.C. (2014). Three-year assessment of Advanced Pharmacy Practice Experience change requests at a large public college of pharmacy. Currents in Pharmacy Teaching and Learning, 6, 767-72.
  1. Chisholm-Burns, M., Spivey, C.A., Phelps, S., McDonough, S., & Byrd, D. (2014). Evaluation of student factors associated with pre-NAPLEX scores. American Journal of Pharmaceutical Education, 78(10), Article 180.
  1. Wang, J., Qiao, Y., Shih, Y.C., Jamison, J.J., Spivey, C.A., Wan, J.Y., White-Means, S.I., Dagogo-Jack, S., Cushman, W.C., & Chisholm-Burns MA. (2014). Effects of Medicare Part D on disparity implications of medication therapy management eligibility criteria. American Health and Drug Benefits, 7(6), 346-358. 
  1. Wang, J., Zhang, Z., Spivey, C., & Chisholm-Burns, M. (2015). Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population. Research in Social and Administrative Pharmacy, 10(6), 904-917. 
  1. Geiger, J.R., Wilks, S.E., Lovelace, L.L., Chen, Z., & Spivey, C.A. (2015). Burden among male, Alzheimer’s caregivers: Effects of distinct coping strategies. American Journal of Alzheimer’s Disease & Other Dementias, 30(3), 238-246.
  1. Spivey, C.A., Qiao, Y., Liu, J., Mardekian, J., Parker, R.B., Phatak, H., Claflin, A.B., Kachroo, S., Abdulsattar, Y., Chakrabarti, A., & Wang, J. (2015). Discontinuation/interruption of warfarin therapy in patients with non-valvular atrial fibrillation. Journal of Managed Care & Specialty Pharmacy, 21(7), 596-606. 
  1. Spivey, C.A., Liu, X., Qiao, Y., Mardekian, J., Parker, R.B., Phatak, H., Masseria, C., Kachroo, S., Abdulsattar, Y., & Wang, J. (2015). Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Current Medical Research and Opinion, 31(11), 2021-2029.
  1. Wang, J., Shih, Y-C., Qin, Y., Young, T., Thomas, Z., Spivey, C.A., Solomon, D., & Chisholm-Burns, M. (2015). Trends in Medicare Part D medication therapy management eligibility criteria. American Health & Drug Benefits, 8(5), 247-255. 
  1. Chisholm-Burns, M., & Spivey, C.A. (2015). Factors associated with student pharmacist philanthropy to the college before and after graduation. American Journal of Pharmaceutical Education, 79(7), Article 102. 
  1. Wang, J., Qiao, Y., Shih, Y.C., Jarrett-Jamison, J., Spivey, C.A., Wan, J.Y., White-Means, S.I., Dagogo-Jack, S., Cushman, W.C., & Chisholm-Burns M.A. (2015). Potential health implications of medication therapy management eligibility criteria in the Patient Protection and Affordable Care Act across racial and ethnic groups. Journal of Managed Care and Specialty Pharmacy, 21(11), 993-1003.
  1. Chisholm-Burns, M., Gatwood, J., & Spivey, C.A. (2015). Economic analysis of obtaining a PharmD degree and a career as a pharmacist. American Journal of Pharmaceutical Education,79(8), Article 117. 
  1. Chisholm-Burns, M.A., Spivey, C.A., Tolley, E.A., & Kaplan, E.K. (2016). Medication therapy management and adherence among US renal transplant recipients. Patient Preference and Adherence, 10, 703-709.
  1. Chisholm-Burns, M.A., Gatwood, J., Spivey, C.A., & Dickey, S.E. (2016). Break-even income analysis of pharmacy graduates compared to high school and college graduates. American Journal of Pharmaceutical Education, 80(3), Article 44. 
  1. Chisholm-Burns, M.A., Gatwood, J., Spivey, C.A., & Dickey, S. (2016). Net income of pharmacy faculty compared to community and hospital pharmacists. American Journal of Pharmaceutical Education, 80(7), Article 117. 
  1. Spivey, C.A., Liu, X., Qiao, Y., Mardekian, J., Parker, R.B., Phatak, H., Masseria, C., Kachroo, S., Abdulsattar, Y., & Wang, J. (2016.) Economic outcomes of warfarin discontinuation among patients with atrial fibrillation. American Journal of Pharmacy Benefits,8(4), 141-148.
  1. Madran, B.B., Karayurt, Ö., Spivey, C.A., & Chisholm-Burns, M.A. (2016.) Validity and Reliability of the Immunosuppressant Therapy Adherence Scale in Turkish Transplant Recipients. Turkiye Klinikleri Journal of Nursing, 8(4), 325-334.
  1. Wang, J., Qiao, Y., Spivey, C., Li, C., Clark, C., Den, Y., Liu, F., Tillman, J., & Chisholm-Burns, M. (2016.) Disparity implications of proposed 2015 Medicare eligibility criteria for medication therapy management services. Journal of Pharmaceutical Health Services Research,7(4), 209-215. 
  1. Chisholm-Burns, M.A., Spivey, C.A., Hagemann, T., & Josephson, M.A. (2017.) Women in leadership and the bewildering glass ceiling. American Journal of Health-System Pharmacy, 74(5) 312-324.
  1. Hohmeier, K., Spivey, C., & Chisholm-Burns, M. (2017.) A community-based partnership collaborative practice agreement project to teach innovation in care delivery. Currents in Pharmacy Teaching and Learning, 9, 473-478. 

29. Chisholm-Burns, M.A., Spivey, C.A., Gatwood, J., Wiss, A., Hohmeier, K., & Erickson, S.R. (2017). Evaluation of racial and socioeconomic disparities in medication pricing and pharmacy access and services. American Journal of Health-System Pharmacy, 74(10), 653-668.

  1. Chisholm-Burns, M.A., Spivey, C.A., Jaeger, M., Williams, J., & George, C. (2017). Development of an instrument to measure pharmacy student attitudes toward social media professionalism. American Journal of Pharmaceutical Education,81(4), Article 65. 
  1. Chisholm-Burns, M.A., Spivey, C.A., Byrd, D.C., McDonough, S.L.K., & Phelps, S.J. (2017). Examining the association between the NAPLEX, Pre-NAPLEX, and pre and post admission factors. American Journal of Pharmaceutical Education, 81(5), Article 86.
  1. Hohmeier, K.C., Spivey, C.A.*, Boldin, S., Moore, T.B., & Chisholm-Burns, M. (2017). Implementation of a health information exchance into community pharmacy workflow. Journal of the American Pharmacists Association, 57(5), 608-615. *corresponding author
  1. Chisholm-Burns, M.A., Spivey, C.A., Jaeger, M.C., & Williams, J.S. (2017). Associations between pharmacy students’ attitudes toward debt, stress, and student loans. American Journal of Pharmaceutical Education 81(7), Article 5918.

 

Wang

Description
Junling Wang, PhD, is a Professor in Health Outcomes and Policy Research at the University of Tennessee Health Science Center, College of Pharmacy. She received her PhD in Pharmaceutical Health Services Research from the University of Maryland in 2005. Dr. Wang has continuously concentrated on the following two research areas: (1) outcomes/economic evaluation of pharmaceutical products and services including medication therapy management; and (2) racial and ethnic disparities in the utilization of health services and prescription drugs. Her research has been funded by the National Institutes of Health (NIH)/National Institute on Aging, Pharmacy Quality Alliance, Pharmaceutical Research and Manufacturers of America Foundation, American Association of Colleges of Pharmacy, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly and Company, and the State of Tennessee. Dr. Wang has published over 50 research articles in peer-reviewed journals. Her work has been cited by the Federal government as reasons for federal policy reform for the Medicare eligibility criteria for medication therapy management services. She has also received recognition for her research including the Nobuo Meade International Research Award and an Honorable Mention for Betty J. Cleckley Minority Issues Research Award from the American Public Health Association (APHA) Aging and Public Health Section. Dr. Wang’s leadership roles have included the APHA Aging and Public Health Section Program Chair, Membership Chair, governing councilor, and Nominations Committee.
Lab Personnel
Research Assistant: Yanru Qiao, MS
Projects
  • “Finding Effective and Equitable MTM Eligibility Criteria.” Source: NIA/NIH. 08/2015-03/2018. $987,562. Role: Principal Investigator.
  • “Impact of Adalimumab Initiation on Co-Therapies and Associated Adverse Effects and Health Services Utilization among Patients with Rheumatoid Arthritis.” Source: AbbVie. 07/01/2017-02/28/2018. Role: Principal Investigator. 
  • “Steroids Utilization and Initiation of Biologic Disease-Modifying Antirheumatic Drugs among Patients with Rheumatoid Arthritis.” Source: AbbVie. 09/2016-04/2017. $98,286. Role: Principal Investigator. 
  • “Patterns of Medication Utilization among Patients with Multiple Chronic Conditions.” Source: Pharmaceutical Research and Manufacturers of America. 11/01/2015-12/31/2017. $60,000. Role: Principal Investigator. 
  • "A Historical Cohort Study on Discontinuation/Interruption of Warfarin Therapy and Outcomes in Patients with Atrial Fibrillation." Source: Pfizer Inc. 07/01/2013-12/31/2015. $204,840. Role: Principal Investigator. 
  • “Health Implications of MTM Eligibility Criteria.” Source: NIA/NIH. 09/2011-06/2015. $892,698. Role: Principal Investigator.
  • “Evaluation of the Effect of Telephonic Medication Therapy Management Services to Medicare Part D Patients on Medication Adherence, Quality and Health Care expenditures (T-MAQ study).” Source: Pharmacy Quality Alliance. 10/10-04/12. $240,000. Role: Co-Principal Investigator (35%).
  •  “Disparity Implications of the Eligibility Criteria for Medication Therapy Management Services.” Source: Pharmaceutical Research and Manufacturers of America Foundation Research Starter Grant in Health Outcomes. 02/09-01/12. $60,000. Role: Principal Investigator.
  • “The Development, Implementation, and Evaluation of a Pharmacy-Based Collaborative Diabetes Management Program.” Source: Roche Diagnostics. 07/07-07/12. $368,460. Role: Co-Investigator ($10,000 or 125 hours effort). Principal Investigator: Kam Nola. 
  • “Duloxetine in the Treatment of Patients with Major Depressive Disorder Comorbid with Chronic Pain.” Source: Eli Lilly and Company. 07/09-12/09. $96,156. Role: Principal Investigator.
  •  “Pharmacists’ Acceptable Levels of Compensation for Medication Therapy Management Services.” Source: American Association of Colleges of Pharmacy New Investigators Program for Pharmacy Faculty. 12/07-12/09. $10,000. Role: Principal Investigator. 
  • “The Effect of Pharmacist Intervention on the Use of Zostavax®  in a Community Pharmacy Setting.” Source: Investigator Initiated Studies Program, Merck & Co. and American Pharmacists Association Foundation Incentive Grant for Practitioner Innovation in Pharmaceutical Care. 01/08-04/09. $18,342. Role: Co-Investigator ($5,000 or 40 hours effort). Principal Investigator: Lindsay J. Ford.
  • “Economic Evaluation of Psychiatric Medication Use in Tennessee among TennCare Pediatric Enrollees.” Source: Bureau of TennCare, Department of Finance and Administration, State of Tennessee. 03/06-08/07. $313,460. Role: Co-Principal Investigator (15% effort). Principal Investigator: Dick R. Gourley.
  • “Preference Based Valuation of Resource Variation in Medication Therapy Management Services.” Source: Pharmaceutical Research and Manufacturers of America Foundation. 01/07-12/08. $60,000. Role: Co-Investigator (5% effort in-kind).  Principal Investigator: Song Hee Hong. 
  • “A Comparison of Direct Medical Costs across Racial and Ethnic Groups among Children with Cancer.” Source: University of Tennessee College of Pharmacy Faculty Seed Grant Award 11/06-06/07. $9,398. Role: Principal Investigator (20% effort in-kind). 
  •  “The Economic Implications of Racial and Ethnic Disparities in the Use of Selective Serotonin Reuptake Inhibitors.” Source: University of Tennessee College of Pharmacy Faculty Seed Grant Award. 11/05-06/06. $5,500. Role: Principal Investigator (20% effort in-kind).
Selected Publications
  1. Lu D, Qiao Y, Brown NE, Wang J. Racial and ethnic disparities in influenza vaccination among adults with chronic medical conditions vary by age in the United States. PLoS One. 2017 Jan 12;12(1):e0169679. doi: 10.1371/journal.pone.0169679.
  2. Tang J, Kaddis A, Bailey J, Chang C, Faris R, Hong SH, Levin M, Wang J. Effects of specialty pharmacy care on health outcomes in multiple sclerosis. American Health & Drug Benefits. 2016;9(8):420-429.
  3. Jamison JJ, Wang J, Surbhi S, Adams S, Solomon D, Hohmeier KC, McDonough S, Eoff JC 3rd. Impact of Medicare Part D on racial and ethnic minorities. Diversity and Equality in Health Care. 2016;13(5):326-333.
  4. Hohmeier KC, McDonough SL, Wang J. Co-creation of market expansion in point-of-care testing in the United States: Industry leadership perspectives on the community pharmacy segment. Research in Social & Administrative Pharmacy. 2016 Oct 27. pii: S1551-7411(16)30236-4. doi: 10.1016/j.sapharm.2016.09.008. [Epub ahead of print]
  5. Lu D, Qiao Y, Johnson KC, Wang J. Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma. Journal of Asthma. 2016 Sep 27:1-10. doi: 10.1080/02770903.2016.1238927. [Epub ahead of print]
  6. Wang J, Qiao Y, Spivey C, Li C, Clark C, Deng Y, Liu F, Tillman J, Chisholm-Burns M. Disparity implications of proposed 2015 Medicare eligibility criteria for medication therapy management services. Journal of Pharmaceutical Health Services Research. 2016;7(4):209-215. doi: 10.1111/jphs.12142.
  7. Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsatter Y, Chakrabarti A, Wang J. Economic outcomes of warfarin discontinuation among patients with atrial fibrillation. American Journal of Pharmacy Benefit. 2016;8(4):141-148. 
  8. Bess DT, Taylor J, Schwab CA, Wang J, Carter J. An innovative approach to pharmacy law education utilizing a mock board of pharmacy meeting. Innovations in Pharmacy. 2016;7(1):Article 9.
  9. Wang J, Qiao Y, Shih YC, Jarrett-Jamison J, Spivey CA, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns M. Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. Journal of Managed Care & Specialty Pharmacy. 2015;21(11):993-1003.
  10. Bell TM, Wang J, Nolly R, Ozdenerol E, Relyea G, Zarzaur BL. Predictors of functional limitation trajectories after injury in a nationally representative U.S. older adult population.Annals of Epidemiology. 2015;25(12):894-900. doi: 10.1016/j.annepidem.2015.08.012.
  11. Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H, Masseria C, Kachroo S, Abdulsattar Y, Wang J. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Current Medical Research & Opinion. 2015; Sep 21:1-9. [Epub ahead of print]
  12. Wang J, Shih Y-CT, Qin Y, Young T, Spivey CA, Thomas Z, Solomon D, Chisholm-Burns M. Trends in Medicare Part D medication therapy management eligibility criteria. American Health and Drug Benefits. 2015;8(5):247-255.
  13. Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsatter Y, Chakrabarti A, Wang J. Discontinuation/interruption of warfarin therapy in patients with non-valvular atrial fibrillation. Journal of Managed Care & Specialty Pharmacy. 2015;21(7):596-606. 
  14. Wang J, Zhang Z, Spivey CA, Chisholm-Burns M. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria in Non-Medicare Population. Research in Social and Administrative Pharmacy. 2014;10(6):904–917.
  15. Wang J, Qiao Y, Shih YC, Jamison JJ, Spivey CA, Li L, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA. Effects of Medicare Part D on disparity implications of medication therapy management eligibility criteria. American Health and Drug Benefits. 2014;7(6):346-358.
  16. Wang J, Qiao Y, Shih YC, Dagogo-Jack S, Spivey CA, Wan JY, White-Means SI, Cushman WC, Chisholm-Burns MA. Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. Journal of Pharmaceutical Health Services Research.2014;5(2):109-118.              
  17. Wang J, Surbhi S, Kuhle J. Receipt of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers among Medicare beneficiaries with diabetes and hypertension. Journal of Pharmaceutical Health Services Research. 2014;5(1):67-74.
  18. Wang J, Munshi K, Hong SH. Racial and ethnic disparities in influenza vaccinations among community pharmacy patients and non-community pharmacy respondents. Research in Social and Administrative Pharmacy. 2014;10(1):126-140.
  19. Wang J, Qiao Y, Shih YC, Wan JY, White-Means SI, Dagogo-Jack S, Cushman WC. Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Research in Social and Administrative Pharmacy. 2014;10(1):106-125. 
  20. Wang J, Qiao Y. Historical trend of disparity implications of Medicare MTM eligibility criteria. Research in Social & Administrative Pharmacy. 2013;9(6):758-769.
  21. Hong SH, Wang J, Tang J. Dynamic view on affordability of fixed dose combination antihypertensive drug therapy. American Journal of Hypertension. 2013;26(7):879-887.
  22. Munshi KD, Shih YC, Brown LM, Dagogo-Jack S, Wan JY, Wang J. Disparity implications of the Medicare MTM eligibility criteria: a literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2013;13(2):201-216.
  23. Hong SH, Wang J, Tak S. A patient-centric goal in time to blood pressure control from drug therapy initiation. Clinical & Translational Science. 2013;6(1):7-12.
  24. Wang J, Ford LJ, Wingate L, Frank SK, Jaber NH, Randolph R, Smith CT, Lane S, Foster SL. The effect of pharmacist intervention on the use of herpes zoster vaccine in a community pharmacy setting. Journal of the American Pharmacists Association. 2013;53(1):46-53.
  25. Wang J, Brown LM, Hong SH. Racial and ethnic disparities in meeting MTM eligibility criteria among the non-Medicare Population. Journal of the American Pharmacists Association. 2012;52(5):e87-96.
  26. Wang J, Hong SH. Contingent valuation and pharmacists' acceptable levels of compensation for medication therapy management services. Research in Social & Administrative Pharmacy. 2012 March 19. [Epub ahead of print]
  27. Ganguli A, Wang J, Gourley DR. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Research in Social & Administrative Pharmacy. 2012;8(2):157-65.  
  28. Hong SH, Liu J, Wang J, Brown LM, White-Means SI. A conjoint analysis of patient preferences on Medicare medication therapy management. Journal of the American Pharmacists Association. 2011;51(3):378-387. 
  29. Wang J, Liu X, Mullins CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Current Medical Research & Opinion. 2011;27(7):1303-13.
  30. Wang J, Hong SH, Brown LM, Meng S. Pharmacists’ acceptable levels of compensation for MTM services: a conjoint analysis. Research in Social & Administrative Pharmacy. 2011;7(4):383-395.
  31. Wang J, Thomas J, Byrd D, Nola K, Liu J. Status of diabetes care among community pharmacy users with diabetes: an analysis of the Medical Expenditure Panel Survey. Journal of the American Pharmacists Association. 2010;50(4):478-484.
  32. Wang J, Mullins CD, Brown LM, Shih YC, Dagogo-Jack S, Hong SH, Cushman WC. Disparity implications of Medicare eligibility criteria for medication therapy management services.Health Services Research. 2010;45(4):1061-1082.
  33. Wang J, Mullins CD, Chang CF, Gourley DR, Shih YC, Dagogo-Jack S, Cushman WC. Comparison of changes over time in per capita health expenditures across racial and ethnic groups. International Journal of Public Policy. 2010;6(3/4):172-189. 
  34. Mullins CD, Seal B, S neoane-Vazquez E, Sankaranrayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. Good research practice for measuring drug costs in cost-effectiveness: Medicare, Medicaid, and other US government payers perspectives: the ISPOR Drug Cost Task Force Report-Part IV. Value in Health. 2010;13(1):18-24.
  35. Saalfrank MA, Wang J, Brown LM. Racial and ethnic differences in health states and the implications for cost utility analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2009:9(4):365-373.
  36. Wang J, Mullins CD, Zuckerman IH, Walker GD, Suda KJ, Yang Y, White-Means SI. Medical Expenditure Panel Survey: a valuable database for studying racial and ethnic disparities in prescription drug use. Research in Social & Administrative Pharmacy. 2008;4(3):206-17.
  37. Wang J, Dong Z, Hong SH, Suda KJ. A comparison of direct medical costs across racial and ethnic groups among children with cancer. Current Medical Research & Opinion. 2008;24(3):847-58.
  38. Wang J, Miller N, Hufstader MA, Bian Y. The health status of Asian Americans and Pacific Islanders and their access to health services. Social Work in Public Health. 2008;23(1):15-43.
  39. Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing new prescription drugs: disparities among non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Health Services Research. 2007;42(4):1499-519.
  40. Wang J, White-Means SI, Hufstader MA, Walker GD. The economic implications of the racial and ethnic disparities in the use of selective serotonin reuptake inhibitors. Current Medical Research & Opinion. 2007;23(4):853-63.
  41. Wang J, Saalfrank MA, Hong SH, Liu C, Gourley DR. Patterns of reporting health-related quality of life across racial and ethnic groups. Expert Review of Pharmacoeconomics & Outcomes Research. 2007;7(2):177-86.
  42. Wang J, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in access to essential new prescription drugs between non-Hispanic Whites, non-Hispanic Blacks, and Hispanic Whites. Medical Care Research & Review. 2006;63(6):742-63.
  43. Mullins CD, Shaya FT, Meng F, Wang J, Bron MS. Comparison of first refill rates among branded SSRI users. Clinical Therapeutics. 2006;28(2):297-305. 
  44. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy. 2005;25(5):660-7. 
  45. Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet C. Economic disparities in treatment costs among ambulatory Medicaid cancer patients. Journal of the National Medical Association. 2004;96(12):1565-74.
  46. Zuckerman IH, Weiss SR, McNally D, Layne B, Mullins CD, Wang J. Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. The American Journal of Managed Care. 2004;10(7):493-500.
  47. Mullins CD, Cooke JL, Wang J, Shaya FT, Hsu VD, Brooks S. Disparities in prevalence rates for lung, colorectal, breast and prostate cancers in Medicaid. Journal of the National Medical Association. 2004;96(6):809-16.
  48. Mullins CD, Wang J, Cooke JL, Blatt L, Baquet CR. Longitudinal versus cross-sectional methodology for estimating the economic burden of breast cancer: a pilot study. Pharmacoeconomics. 2004;22(5):285-91.
  49. Mullins CD, Wang J, Stoller J. Major components of the direct medical costs of a1-antitrypsin deficiency. Chest. 2003;124(3):826-31.
  50. Mullins CD, Blatt L, Wang J. Societal implications of the pharmacoeconomics of a1-antitrypsin deficiency. Expert Review of Pharmacoeconomics & Outcomes Research. 2002; 2(3):243-9. 
  51. Mullins CD, Wang J. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. Pharmacoeconomics. 2002;20(1):9-21.
  52. Mullins CD, Wang J, Palumbo FB, Stuart B. The impact of pipeline drugs on drug spending growth. Health Affairs. 2001;20(5):210-5.

Last Published: Mar 20, 2019